You are here

Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI152873-01
Agency Tracking Number: R41AI152873
Amount: $583,828.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA19-270
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-05-01
Award End Date (Contract End Date): 2022-04-30
Small Business Information
6405 CEDAR WATERS DR
Raleigh, NC 27607-5175
United States
DUNS: 081290760
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOSHUA PIERCE
 (919) 513-1489
 jgpierce@ncsu.edu
Business Contact
 JOSHUA PIERCE
Phone: (412) 417-4723
Email: jgpierce@synoxasciences.com
Research Institution
 NORTH CAROLINA STATE UNIVERSITY RALEIGH
 
2601 WOLF VILLAGE WAY
RALEIGH, NC 27695-0001
United States

 Nonprofit College or University
Abstract

Project Summary
Natural products have served as a productive source of drugs over the past decades and have
represented, or been the inspiration for, a majority of antimicrobial compounds that have entered
the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine
natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These
scaffolds have the potential to clear biofilm-implicated recalcitrant infections based on preliminary
in-vitro data. These biofilm-implicated infections are tolerant to traditional antibiotics and represent
a significant clinical need since up to 80% of human infections involve biofilm-associated
microorganisms. Few small molecules have been isolated that have the potential to disrupt
biofilms, thereby functioning to clear biofilm associated infections. Herein, we propose to develop
a class of compounds that is capable to addressing the treatment of biofilm associated infections
and generate the key data necessary for a go/no-go decision to advance these molecules toward
a Phase II pre-clinical study.Project Narrative
This proposal aims to develop novel therapeutics for the treatment of recalcitrant Gram-positive
bacterial infections. Specifically, this work will enable key data to focus and direct the
commercialization of the 4-oxazolidinone family of natural products, molecules that have
displayed unusual activity against bacterial biofilms and persister cells. The results obtained from
these studies are essential for identifying a lead compound for future preclinical studies and an
Investigational New Drug (IND) application.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government